Biomarkers are detectable molecules that can reflect specific physiological states of cells,
organs, and organisms and therefore be regarded as indicators for specific diseases. And …

Ponatinib is a third‐generation BCR:: ABL1 tyrosine kinase inhibitor (TKI) with high potency
against Philadelphia chromosome (Ph)‐positive leukemias, including T315I‐mutated …

BH3 mimetics, targeting the Bcl-2 family anti-apoptotic proteins, represent a promising
therapeutic opportunity in cancers. ABT-199, the first specific Bcl-2 inhibitor, was approved …

Blinatumomab is a BiTE®(bispecific T‐cell engager) molecule that redirects CD3+ T‐cells to
engage and lyse CD19+ target cells. Here we demonstrate that subcutaneous (SC) …

Simple Summary Immunotherapy has improved the outcome of relapsed/refractory B-
lymphoblastic leukemia. However, little is known about the outcome after recurrence and re …

The treatment of childhood acute lymphoblastic leukemia (ALL) has reached overall survival
rates exceeding 90%. The present and future challenges are to cure the remainder of …

Galectin-9 (Gal-9) is a vital member of the galectin family, functioning as a multi-subtype
galactose lectin with diverse biological roles. Recent research has revealed that Gal-9's …

In the field of contemporary medicine, autoimmune diseases (AIDs) are a prevalent and
debilitating group of illnesses. However, they present extensive and profound challenges in …

Inotuzumab ozogamicin (INO) is an anti-CD22 antibody-drug conjugate that was first
evaluated in B-cell lymphomas but was subsequently shown to be highly effective in acute …

Molecular targeted drugs and chimeric antigen receptor (CAR) T cell therapy represent
specific biological treatments that have significantly improved the efficacy of treating …